Pentanoic Acid, 2-propyl-, 2-propylpentyl Ester | 58175-58-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Pentanoic Acid, 2-propyl-, 2-propylpentyl Ester
• 英文别名: 2-propylpentyl 2-propylpentanoate
• CAS: 58175-58-9
• 化学式: C₁₆H₃₂O₂
• 分子量: 256.42
• InChiKey: HYECXRALZCEONB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  18
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Pharmaceutical compound and method
  申请人：Bruno-Blanch Luis

  公开号：US20070219164A1

  公开（公告）日：2007-09-20

  A new pharmaceutical compound for treating central nervous disorders, the compound comprising a therapeutically effective amount of valproic acid or pharmaceutically acceptable derivative thereof covalently bonded to myo-inositol. The invention also provides a composition, method for treating a patient and a method for obtaining the compound.

  一种用于治疗中枢神经系统疾病的新药物化合物，该化合物包括治疗有效量的丙戊酸或其药用可接受的衍生物与肌醇共价结合。该发明还提供了一种组合物、治疗患者的方法以及获得该化合物的方法。
• 1'-Ethoxycarbonyloxyethyl ester of valproic acid, its preparation and formulations containing it
  申请人：Teva Pharmaceutical Industries Limited

  公开号：EP0114720A1

  公开（公告）日：1984-08-01

  The novel 1'ethoxycarbonyloxyethyl ester of di-n-propyiacetic acid, also known as valproic acid, may be prepared by reacting valproic acid with a 1-haloethyl ethyl carbonate. There are also provided pharmaceutical or veterinary formulations, e.g. for oral administration, containing the said ester.

  新型二正丙基乙酸 1'乙氧基羰基氧乙基酯，又称丙戊酸，可通过丙戊酸与 1-卤乙基碳酸乙酯反应制备。此外，还提供了含有上述酯类的药物或兽药制剂，例如用于口服的制剂。
• Sustained release compositions containing valproic acid
  申请人：YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM

  公开号：EP0442012A1

  公开（公告）日：1991-08-21

  The invention relates to controlled release pharmaceutical compositions. These contain as active ingredient valproic acid, a salt of valproic acid, an ester of valproic acid, Valpromide, or any other pharmaceutically acceptable derivative of valproic acid which upon administration to humans provides a serum level of valproic acid, in combination with an additive which is selected from physiologically acceptable polymeric substances and from native proteins. The active ingredient is usually in the range of from 10 to 80 weight per cent. The novel pharmaceutical compositions are prepared by applying a high pressure to a mixture of the ingredients. They result in a prolonged serum level of the active ingredient.

  本发明涉及控释药物组合物。它们含有作为活性成分的丙戊酸、丙戊酸的盐、丙戊酸的酯、丙戊酸钠或任何其他药学上可接受的丙戊酸衍生物，在给人用药后可提供一定水平的丙戊酸血清，同时还含有一种添加剂，该添加剂选自生理学上可接受的聚合物质和本地蛋白质。活性成分的重量百分比通常在 10%至 80%之间。新型药物组合物是通过对成分混合物施加高压来制备的。它们能延长血清中活性成分的含量。
• Controlled release sodium valproate formulation
  申请人：Podhipleux Nilobon

  公开号：US20050276850A1

  公开（公告）日：2005-12-15

  Disclosed is a controlled release formulation comprising valproic acid, pharmaceutically acceptable salt thereof, amide thereof, or derivative thereof.

  所公开的是一种控释制剂，包含丙戊酸、其药学上可接受的盐、其酰胺或其衍生物。
• Sustained-release drug dosage units
  申请人：ABBOTT LABORATORIES

  公开号：EP0430287B2

  公开（公告）日：2000-07-12